TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

Ian J Majewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.